Cite
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands.
MLA
Spanjaart, Anne M., et al. “The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands.” Cancers, vol. 15, no. 17, Sept. 2023, p. 4334. EBSCOhost, https://doi.org/10.3390/cancers15174334.
APA
Spanjaart, A. M., Pennings, E. R. A., Mutsaers, P. G. N. J., van Dorp, S., Jak, M., van Doesum, J. A., de Boer, J. W., Niezink, A. G. H., Kos, M., Vermaat, J. S. P., Sijs-Szabo, A., van der Poel, M. W. M., Nijhof, I. S., Kuipers, M. T., Chamuleau, M. E. D., Lugtenburg, P. J., Doorduijn, J. K., Serroukh, Y. I. M., Minnema, M. C., & van Meerten, T. (2023). The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands. Cancers, 15(17), 4334. https://doi.org/10.3390/cancers15174334
Chicago
Spanjaart, Anne M., Elise R. A. Pennings, Pim G. N. J. Mutsaers, Suzanne van Dorp, Margot Jak, Jaap A. van Doesum, Janneke W. de Boer, et al. 2023. “The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands.” Cancers 15 (17): 4334. doi:10.3390/cancers15174334.